Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · USD

$38.5

+0.54 (+1.4%)· Recorded snapshot

Market cap	2.2B
Revenue (ttm)	959.9M
Net income (ttm)	181.3M
EPS (ttm)	$3.09
Shares out	58.2M
P/E (trailing)	12.5x
P/E (forward)	9.6x
Volume	629,294
Beta	1.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 959.9M
Net income (ttm): 181.3M
EPS (ttm): $3.09
P/E (trailing): 12.5x
P/E (forward): 9.6x
Market cap: 2.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E9.6

P25 n/aP50 n/aP75 n/a

Trailing P/E12.5

P25 n/aP50 n/aP75 n/a

ROE20.5

P25 n/aP50 n/aP75 n/a

ROIC37.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HRMY indicators

Market & fundamental data

Available fields

266

Groups with data

Currency

USD

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001802665
Company name	Harmony Biosciences Holdings, Inc.
Country	United States
Country code	US
CUSIP number	413197104
Earnings date	2026-11-04
Earnings time	bmo
Employees	293
Employees change	25
Employees growth	9.33%
Enterprise value	$1.7B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-08-19
Is primary listing	Yes
Is SPAC	No
ISIN number	US4131971040
Last 10-K release date	2026-02-24
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.2B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$38.49
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	HRMY
U.S. state	Pennsylvania
Website	https://www.harmonybiosciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.78x
Average P/E ratio (3Y)	12.99x
Average P/E ratio (5Y)	28.96x
Earnings yield	8.03%
EV/Earnings	9.43x
EV/EBIT	7.41x
EV/EBITDA	6.68x
EV/FCF	4.82x
EV/Sales	1.78x
FCF / EV yield	20.77%
FCF yield	16.01%
Forward EV/Sales	1.55x
Forward P/E	9.61x
Forward P/S	2.01x
Graham number	34.57899
Graham upside	-9.15%
Lynch fair value	$77.28
Lynch upside	103.04%
P/(FCF - SBC) ratio	7.06x
P/(OCF - SBC) ratio	7.05x
P/B ratio	2.21x
P/E ratio	12.45x
P/FCF ratio	6.25x
P/OCF ratio	6.24x
P/S ratio	2.31x
PEG ratio	0.29x
Price / tangible book value	2.4x
Price/EBITDA ratio	8.66x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	24.03%
EBITDA margin	26.67%
Effective tax rate	24.85%
FCF margin	36.97%
Gross margin	75.42%
Operating margin	24.03%
Pretax margin	25.13%
Profit margin	18.88%
Profit per employee	$618,669
Profitable quarters	19
Profitable years	5
Revenue per employee	$3.3M
ROA	11.62%
ROA (5Y)	13.42%
ROCE	20.25%
ROE	20.46%
ROE (5Y)	32.44%
ROIC	37.45%
ROIC (5Y)	54.66%
SBC / revenue	4.26%
Tax / revenue	6.24%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-0.15%
EPS growth (Q)	88.24%
EPS growth (QoQ)	132.73%
EPS growth 3Y	-1.92%
EPS growth 5Y	55.71%
EPS growth quarters	1
EPS growth years	2
FCF growth	37.17%
FCF growth (Q)	16.53%
FCF growth (QoQ)	232.97%
FCF growth 3Y	30.09%
FCF growth 5Y	48.42%
Gross profit growth	19.63%
Gross profit growth (Q)	22.02%
Gross profit growth 3Y	21.54%
Gross profit growth 5Y	30.07%
Net income growth	0.2%
Net income growth (Q)	89.64%
Net income growth (QoQ)	132.18%
Net income growth 3Y	-3.26%
Net income growth 5Y	60.18%
Net income growth quarters	1
Net income growth years	2
OCF growth	36.9%
OCF growth (Q)	16.52%
OCF growth (QoQ)	232.97%
OCF growth 3Y	30.03%
OCF growth 5Y	48.31%
Operating income growth	3.96%
Operating income growth (Q)	85.38%
Operating income growth 3Y	16.24%
Operating income growth 5Y	32.73%
Revenue growth	24.25%
Revenue growth (Q)	30.32%
Revenue growth (QoQ)	21.31%
Revenue growth 3Y	24.38%
Revenue growth 5Y	32.46%
Revenue growth quarters	23
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-178,000
Depreciation and amortization	$25.3M
EBIT	$230.7M
EBITDA	$256M
EPS	$3.09
FCF per share	$6.09
Financing cash flow	$-13.8M
Free cash flow	$354.9M
Free cash flow minus SBC	$314M
Gross profit	$724M
Income taxes	$59.9M
Investing cash flow	$-337.6M
Net borrowing	$-18.8M
Net cash flow	$3.7M
Net income	$181.3M
Operating cash flow minus SBC	$314.2M
Operating income	$230.7M
Revenue	$959.9M
Stock-based compensation	$40.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.08
Book value per share	$17.19
Debt / EBITDA	0.62
Debt / equity	0.16
Debt / FCF	0.45
Interest coverage	17.12
Long-term assets	$558.8M
Long-term liabilities	$139.8M
Net cash (debt)	$507.6M
Net cash / market cap	22.9%
Net cash growth	29.52%
Net debt / EBITDA	-1.98
Net debt / equity	-0.51
Net debt / FCF	-1.43
Piotroski F-Score	5
Property, plant and equipment	$5.8M
Shareholders' equity	$999.2M
Tangible book value	$921.7M
Tangible book value per share	$15.86
Total assets	$1.4B
Total cash	$667.8M
Total debt	$160.2M
Total liabilities	$373.8M
WACC	9.57%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.77
Current assets	$814.3M
Current liabilities	$234.1M
Current ratio	3.48
Inventory turnover	37.87
Net working capital	$-66.1M
Quick ratio	3.33
Working capital	$580.3M
Working capital turnover	1.76

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.65%
Dividend yield	0%
Shareholder yield	-0.65%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$35.36
1D price change	1.42%
1M price change	-7.49%
1M total return	-7.49%
1W price change	-1.37%
1W total return	-1.37%
1Y price change	26.77%
1Y return CAGR	26.79%
1Y total return	26.77%
20-day SMA	$38.32
200-day SMA	$34.66
3M price change	6%
3M total return	6%
3Y price change	98.8%
3Y return CAGR	25.73%
3Y total return	98.8%
50-day SMA	$39.77
50-day SMA vs 200-day SMA	50over200
52-week high	$43.49
52-week high date	2026-09-03
52-week low	$25.90
52-week low date	2026-02-24
5Y price change	-6.17%
5Y return CAGR	-1.27%
5Y total return	-6.17%
6M price change	22.93%
6M total return	22.93%
All-time high	$62.09
All-time high date	2022-12-05
All-time low	$18.61
All-time low date	2023-10-13
Average true range (ATR)	$1.58
Average volume	1M
Beta (1Y)	0.68
Beta (2Y)	1.05
Beta (5Y)	1.01
Change from 52-week high	-11.5%
Change from 52-week low	48.6%
Change from all-time high	-38.52%
Change from all-time low	105.09%
Change from open	2.26%
Day's gap	-0.82%
Dollar volume	$24.2M
High price	$38.49
Low price	$37.43
Monthly RSI	54.67
Open price	$37.64
Position in 52-week range	100%
Premarket change	-0.66%
Premarket close	$37.95
Premarket price	$37.70
Premarket volume	1.4K
Previous close	$37.95
Price vs 150-day SMA	7.95%
Price vs 20-day SMA	-0.39%
Price vs 200-day SMA	10.12%
Price vs 50-day SMA	-4.02%
Relative volume	0.61
Return from IPO open	-4.83%
Return from IPO price	58.58%
RSI	47.88
Sharpe ratio	0.7
Sharpe ratio (3Y)	0.63
Sharpe ratio (5Y)	0.14
Sortino ratio	1.13
Sortino ratio (3Y)	1.05
Sortino ratio (5Y)	0.29
Volume	629.3K
Weekly RSI	53.47
YTD price change	2%
YTD total return	2%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52.1M
Float percentage	89.45%
Shares change (QoQ)	-0.04%
Shares change (YoY)	0.65%
Shares held by insiders	0.11%
Shares held by institutions	97.52%
Shares outstanding	58.2M
Short % of float	10.39%
Short % of shares	9.3%
Short ratio	5.1 days

Deeper analysis on HRMY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this HRMY report

Is a complete HRMY research report available?

No complete published report is available for Harmony Biosciences Holdings, Inc. (HRMY) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Harmony Biosciences Holdings, Inc. (HRMY)

Price

Financial snapshot

Fair-value bridge

Latest news · HRMY

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HRMY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HRMY

Frequently asked questions